Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Creatine may increase hair shedding for some, especially those sensitive to DHT, but experiences vary. Many users on finasteride and minoxidil report no additional hair loss from creatine.

The user shared their experience with Finasteride and Dutasteride for hair loss. They initially had success with Finasteride but switched to Dutasteride after experiencing shedding, which continued, and are now considering a hair transplant.

The user experienced significant hair regrowth using a topical solution of minoxidil 5% and finasteride 0.1% over 100 days, with plans to continue for a year before switching to a maintenance dose. Despite skepticism from others about using hair fibers, the user insists on the authenticity of their progress and reports no side effects from the treatment.

The user experienced significant hair regrowth using 1mg finasteride and 2mg minoxidil daily, along with Nizoral shampoo and rosemary oil. They are curious about further improving hair density and whether increasing the minoxidil dose would help.

A user experienced significant hair regrowth using finasteride 1 mg daily for two years and gradually introduced dutasteride 0.5 mg daily over four months. They reported no side effects and plan to switch fully to dutasteride due to its cost-effectiveness and potential effectiveness.

The conversation discusses switching from finasteride to dutasteride for hair loss treatment, with users sharing experiences of shedding and gradual transition methods. Some users report continued shedding, while others are hopeful for thicker hair after the switch.

Finasteride and Dutasteride do not cause depression or mood disorders; hair loss itself may be a more significant factor. Some users experience side effects from Finasteride, but it is generally well-tolerated.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Finasteride may affect neurosteroids, impacting mood and sexual function, with varied user experiences. Some report side effects like depression and sexual dysfunction, while others find it effective for hair retention or prefer alternatives like Dutasteride or topical treatments.

Tazarotene may outperform tretinoin for hairline treatment with minoxidil, but lacks evidence. Tretinoin is recommended for the scalp, while tazarotene can be used on the face.

Hair loss is linked to a higher rate of body dysmorphic disorder (BDD), OCD, and depression. Finasteride and dutasteride are not linked to increased suicidal risk, though some users report mental health side effects.

Hair loss is reportedly starting earlier in younger generations, with potential causes including prediabetes and decreased dietary minerals and vitamins. Minoxidil is mentioned as a treatment that supports capillary health and promotes hair growth.

The conversation discusses hair loss treatments for a 30-year-old female, comparing red light therapy with minoxidil and finasteride. Concerns about hormonal impact and potential pregnancy are raised, with suggestions to consider spironolactone and microneedling, while emphasizing the importance of consulting a dermatologist.

The user has been battling hair loss for five years using Minoxidil, Finasteride, and Dutasteride. Despite some improvements, hair loss persists, and they are considering dietary changes and other treatments for seborrheic dermatitis and hyperhidrosis.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

Dutasteride has been used for 20 years with some hair thickness improvement but no dramatic regrowth. The user also experimented with minoxidil, tretinoin, and peptides like BPC 157 for potential benefits in hair density and quality.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation discusses using both oral and topical minoxidil for hair loss, with some users reporting mixed results and concerns about potential side effects. The original poster uses topical finasteride and oral minoxidil and is considering adding topical minoxidil and tretinoin to their regimen.

The conversation discusses treatments for androgenetic alopecia, focusing on evidence-based supplements to complement finasteride. Suggestions include oral minoxidil, saw palmetto, pumpkin seed oil, tocotrienols, and various other supplements, while emphasizing the importance of scientific backing and cautioning against saw palmetto if already using finasteride.

The user saw hair improvement with minoxidil, finasteride, and a red light cap, noting better results after adding finasteride and stressing routine consistency.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

Scalp tension from the occipitalis muscle is theorized to contribute to hair loss, but most believe DHT and genetics are the main causes. Treatments like finasteride and minoxidil are considered more effective than addressing scalp tension.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Oral minoxidil is effective for hair loss but can cause cardiovascular side effects, such as pericardial effusion, especially in those with genetic predispositions. Starting with low doses and monitoring cardiovascular health are advised to reduce risks.

A 31-year-old woman is using Dutasteride (0.5mg daily) and supplements like a multivitamin, Herbadal, pumpkin seed oil, and vitamin D for genetic hair loss, noticing thicker hair but no new growth after one month. She is considering adding minoxidil and is aware of Dutasteride's risks, especially regarding pregnancy.